Skip to content
Exits and Outcomes
Sign In
Subscribe
Digital health research, news, and analysis from Brian Dolan.
$200/year or
consider an Enterprise subscription
.
Prescription Digital Therapeutics
All Newsletters
216 articles
17 of 22
FDA SaMD risk categories, OUD guidance in 2021?
10.16.20
5
min. Read
Five pharma companies talk digital therapeutic partnerships, DTx pricing, and more
10.09.20
21
min. Read
Pharma execs talk digital therapeutic pricing. Germany reimburses first two prescribable apps.
10.09.20
7
min. Read
Five investors talk digital therapeutics: Red flags, starting up, and COVID–19
10.02.20
14
min. Read
Proteus founders explain. Investors talk DTx.
10.02.20
8
min. Read
Apple eyes asthma, sleep apnea SaMDs? Amwell-Teladongo suit.
9.18.20
8
min. Read
32 Pear patents. Amwell $644M IPO.
9.11.20
6
min. Read
New Teladongo merger details. Pear’s acquisitive study strategy.
9.04.20
8
min. Read
20 percent of Rx-only digital therapeutics have studies so far.
8.14.20
9
min. Read
Livongo’s IPO anniversary. DTx pipelines.
7.24.20
7
min. Read
1 of 22